LionBio is a preclinical biotech developing a novel intranasal GLP-1 formulation. CEO Robin Guo needed to make commercial positioning decisions before a single trial reads out, in a market with hundreds of assets that is getting increasingly crowded.

Demand for GLP-1s means there is clear market opportunity, but LionBio's positioning is less clear. Orals are approved, convenience is commoditizing, and long acting compounds are in development. The question is, where can a nasal formulation carve a niche?

Robin defined the questions: which segments, channels, and competitors should be analyzed? Sleuth ran analysis across all three simultaneously, connecting market dynamics to clinical evidence to regulatory precedent in one traceable deliverable. 714 GLP-1 programs screened. 80 competitive non-injectables profiled. 12 discontinuation studies synthesized. 9 FDA precedents analyzed for regulatory path. 3 candidate patient segments pressure-tested.

Robin landed on a commercial strategy grounded in evidence he can challenge, trust, and cite. He could see which positioning instincts held up, which ones didn't, and where to allocate preclinical resources to close the gaps that matter most. Comprehensive commercial strategy delivered in three weeks.